Literature DB >> 12861138

Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety.

Ettore Cicinelli1, Edoardo Di Naro, Dominique De Ziegler, Maria Matteo, Stella Morgese, Pietro Galantino, Pierre-Alain Brioschi, AndSergio Schonauer.   

Abstract

OBJECTIVE: The purpose of this study was to investigate whether the effects of 17beta-estradiol tablets that are designed for the treatment of postmenopausal urovaginal atrophy are influenced by the site of placement into the vagina. STUDY
DESIGN: In this controlled crossover trial, 10 postmenopausal women received a single 17beta-estradiol tablet in the outer or inner one third of the vagina. Before and 3 hours after treatment, the pulsatility index, resistance index, and blood flow were evaluated in the uterine and periurethral vessels by Doppler examination. Parallel 17beta-estradiol serum evaluations were performed.
RESULTS: Comparable and significant increases in 17beta-estradiol were observed. After inner administration, the pulsatility index and resistance index of both uterine arteries decreased; uterine artery blood flow increased significantly (P <.0001) but decreased in periurethral vessels (P <.02). After outer administration, the uterine artery pulsatility index, resistance index, and blood flow did not change, and the periurethral blood flow significantly increased (P <.0001).
CONCLUSION: For optimizing the efficacy while minimizing the risk of endometrial hyperplasia, 17beta-estradiol tablets must be placed in the outer one third of the vagina.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12861138     DOI: 10.1067/mob.2003.341

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle.

Authors:  Ruben J Kuon; Shao-Qing Shi; Holger Maul; Christof Sohn; James Balducci; William L Maner; Robert E Garfield
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

2.  Estrogen Replacement Therapy to Prevent Recurrent Urinary Tract Infection in Postmenopausal Women.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

Review 3.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

Review 4.  Vaginal rings for menopausal symptom relief.

Authors:  Susan A Ballagh
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.

Authors:  Sheryl A Kingsberg; Lisa Larkin; Michael Krychman; Sharon J Parish; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-02       Impact factor: 2.953

6.  Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review.

Authors:  Ginger D Constantine; Shelli Graham; Kate Lapane; Kathleen Ohleth; Brian Bernick; James Liu; Sebastian Mirkin
Journal:  Menopause       Date:  2019-07       Impact factor: 2.953

7.  Seminal plasma promotes decidualization of endometrial stromal fibroblasts in vitro from women with and without inflammatory disorders in a manner dependent on interleukin-11 signaling.

Authors:  Ashley F George; Karen S Jang; Mette Nyegaard; Jason Neidleman; Trimble L Spitzer; Guorui Xie; Joseph C Chen; Eytan Herzig; Anders Laustsen; Erika G Marques de Menezes; Sahar Houshdaran; Christopher D Pilcher; Philip J Norris; Martin R Jakobsen; Warner C Greene; Linda C Giudice; Nadia R Roan
Journal:  Hum Reprod       Date:  2020-03-27       Impact factor: 6.918

Review 8.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

9.  Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation.

Authors:  Yongmei Huang; Ruth B Merkatz; Sharon L Hillier; Kevin Roberts; Diana L Blithe; Régine Sitruk-Ware; Mitchell D Creinin
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

10.  Systemic estradiol levels with low-dose vaginal estrogens.

Authors:  Richard J Santen; Sebastian Mirkin; Brian Bernick; Ginger D Constantine
Journal:  Menopause       Date:  2020-03       Impact factor: 3.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.